Nevin Murray

8.4k total citations · 3 hit papers
121 papers, 6.2k citations indexed

About

Nevin Murray is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nevin Murray has authored 121 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 30 papers in Molecular Biology. Recurrent topics in Nevin Murray's work include Lung Cancer Research Studies (53 papers), Lung Cancer Treatments and Mutations (38 papers) and Neuroendocrine Tumor Research Advances (25 papers). Nevin Murray is often cited by papers focused on Lung Cancer Research Studies (53 papers), Lung Cancer Treatments and Mutations (38 papers) and Neuroendocrine Tumor Research Advances (25 papers). Nevin Murray collaborates with scholars based in Canada, United States and United Kingdom. Nevin Murray's co-authors include Joseph L. Pater, William K. Evans, Andrew Arnold, Ronald Feld, Scott Tyldesley, Yvon Cormier, Benny Zee, E Rapp, Michael McKenzie and William Morris and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Nevin Murray

119 papers receiving 6.0k citations

Hit Papers

Chemotherapy can prolong ... 1988 2026 2000 2013 1988 1993 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
    1988 544 citations Joseph L. Pater, Yvon Cormier et al. Journal of Clinical Oncology profile →
  2. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
    1993 515 citations Nevin Murray, Joseph L. Pater et al. Journal of Clinical Oncology profile →
  3. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
    2016 505 citations Scott Tyldesley, Nevin Murray et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Nevin Murray 3.3k 3.3k 1.4k 1.4k 932 121 6.2k
Élisabeth Quoix 5.1k 1.5× 5.4k 1.7× 2.0k 1.4× 1.3k 0.9× 541 0.6× 256 8.3k
Martine Antoine 2.2k 0.7× 2.4k 0.7× 1.0k 0.7× 532 0.4× 760 0.8× 188 5.5k
Ranjan Sur 3.0k 0.9× 3.0k 0.9× 1.3k 0.9× 386 0.3× 2.2k 2.4× 68 6.4k
Francis P. Worden 3.5k 1.0× 2.3k 0.7× 1.7k 1.2× 848 0.6× 3.1k 3.3× 257 9.1k
A. Dimitrios Colevas 3.4k 1.0× 2.1k 0.6× 1.6k 1.1× 514 0.4× 2.2k 2.4× 197 7.6k
Stephen L. Graziano 2.8k 0.8× 2.9k 0.9× 1.3k 0.9× 559 0.4× 459 0.5× 117 5.2k
Marco Alloisio 1.7k 0.5× 3.0k 0.9× 884 0.6× 336 0.2× 843 0.9× 157 4.6k
Salma K. Jabbour 2.1k 0.6× 2.1k 0.7× 503 0.4× 549 0.4× 853 0.9× 244 4.3k
Mary F. Mulcahy 4.0k 1.2× 3.2k 1.0× 1.2k 0.8× 3.1k 2.2× 3.1k 3.3× 220 11.7k
Haruhiko Kondo 2.2k 0.7× 4.2k 1.3× 821 0.6× 806 0.6× 1.4k 1.5× 205 6.5k

Countries citing papers authored by Nevin Murray

Since Specialization
Citations

This map shows the geographic impact of Nevin Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nevin Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nevin Murray more than expected).

Fields of papers citing papers by Nevin Murray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nevin Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nevin Murray. The network helps show where Nevin Murray may publish in the future.

Co-authorship network of co-authors of Nevin Murray

This figure shows the co-authorship network connecting the top 25 collaborators of Nevin Murray. A scholar is included among the top collaborators of Nevin Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nevin Murray. Nevin Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wheatley‐Price, Paul, Quincy S. Chu, Maria Bonomi, et al.. (2016). A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Journal of Thoracic Oncology. 11(11). 2018–2021. 29 indexed citations
2.
Noonan, Krista, Janessa Laskin, Yulong Zheng, et al.. (2015). Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. Clinical Oncology. 27(9). 505–513. 4 indexed citations
3.
Noonan, Krista, Janessa Laskin, Barbara Melosky, et al.. (2014). Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort. Lung Cancer. 86(3). 344–349. 21 indexed citations
4.
Sridhar, Srikala S., Mary J. MacKenzie, Sébastien J. Hotte, et al.. (2013). A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Investigational New Drugs. 31(4). 1008–1015. 20 indexed citations
5.
Lockwood, William W., Ian M. Wilson, Bradley P. Coe, et al.. (2012). Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development. PLoS ONE. 7(5). e37775–e37775. 40 indexed citations
6.
Vinod, Shalini, Elaine S. Wai, Cheryl Alexander, Scott Tyldesley, & Nevin Murray. (2012). Stage III Non–Small-Cell Lung Cancer: Population-Based Patterns of Treatment in British Columbia, Canada. Journal of Thoracic Oncology. 7(7). 1155–1163. 31 indexed citations
7.
Laurie, Scott A., Ashish Gupta, Quincy S. Chu, et al.. (2011). Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. Journal of Thoracic Oncology. 6(11). 1950–1954. 52 indexed citations
8.
Palma, David A., Scott Tyldesley, Islam Mohamed, et al.. (2010). Stage I Non-small Cell Lung Cancer (NSCLC) in Patients Aged 75 Years and Older: Does Age Determine Survival After Radical Treatment?. Journal of Thoracic Oncology. 5(6). 818–824. 32 indexed citations
9.
Michels, Jorg, Susan Ellard, Lyly Le, et al.. (2009). A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Annals of Oncology. 21(2). 305–311. 18 indexed citations
10.
Heng, Daniel Y.C., Kim N., Nevin Murray, et al.. (2009). A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 115(4). 776–783. 50 indexed citations
11.
Sridhar, Srikala S., Mary J. MacKenzie, Sébastien J. Hotte, et al.. (2007). AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.. Molecular Cancer Therapeutics. 6. 1 indexed citations
12.
Butts, Charles, Andrew W. Maksymiuk, Glenwood Goss, et al.. (2007). B1-01: A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. Journal of Thoracic Oncology. 2(8). S332–S333. 36 indexed citations
13.
14.
Kim, KyungMann & Nevin Murray. (2007). WS-07: Designs for vaccine and immunotherapy trials. Journal of Thoracic Oncology. 2(8). S293–S294. 1 indexed citations
15.
Laurie, Scott A., Keyue Ding, Ronald Feld, et al.. (2007). The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology. 18(6). 1051–1055. 10 indexed citations
16.
Murray, Nevin & Andrew T. Turrisi. (2006). A Review of First-Line Treatment for Small-cell Lung Cancer. Journal of Thoracic Oncology. 1(3). 270–278. 102 indexed citations
17.
18.
Erridge, Sara & Nevin Murray. (2003). Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation. Seminars in Oncology. 30(1). 26–37. 27 indexed citations
19.
Moore, Malcolm J., Ian F. Tannock, D. Scott Ernst, S. Huan, & Nevin Murray. (1997). Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.. Journal of Clinical Oncology. 15(12). 3441–3445. 222 indexed citations
20.
Siu, L.L., Frances A. Shepherd, Nevin Murray, et al.. (1996). Influence of age in the treatment of limited-stage small-cell lung cancer. Pneumologie. 50(7). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Élisabeth Quoix Breakdown of academic impact, for papers by Martine Antoine Breakdown of academic impact, for papers by Ranjan Sur Breakdown of academic impact, for papers by Francis P. Worden Breakdown of academic impact, for papers by A. Dimitrios Colevas Breakdown of academic impact, for papers by Stephen L. Graziano Breakdown of academic impact, for papers by Marco Alloisio Breakdown of academic impact, for papers by Salma K. Jabbour Breakdown of academic impact, for papers by Mary F. Mulcahy Breakdown of academic impact, for papers by Haruhiko Kondo
Rankless by CCL
2026